Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

Launched by ALEXANDRIA UNIVERSITY · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called finerenone in patients who have a specific type of kidney disease known as non-diabetic glomerulonephritis. The main goals are to see if finerenone can reduce protein in the urine (which is a sign of kidney damage) and slow down the progression of kidney function loss. The trial is currently looking for participants aged 18 and older who have been on certain medications for their kidney condition for at least four weeks and have specific kidney function levels.

To be eligible for the trial, participants must have high levels of protein in their urine and meet certain health criteria, like having stable kidney function and not having diabetes. Unfortunately, individuals with other serious health issues like heart failure or uncontrolled high blood pressure cannot participate. If eligible, participants will receive finerenone and be closely monitored throughout the study to understand how the medication affects their kidney health. This trial provides a valuable opportunity to contribute to research that may help improve treatment options for kidney disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. GN patients on maximum tolerated doses of an ACEi or ARBs together with their immunosuppression protocol (if needed) for at least 4 weeks.
• • 2. urinary protein excretion \>500 mg/g.
• • 3. Adult patients with age above 18 years.
• • 4. eGFR ≥ 25 mL/ min/1.73 m2.
• • 5. baseline serum potassium level \<5 mEq/L.
• Exclusion Criteria:
• • 1. Patients with diabetes mellitus (type 1 or 2).
• • 2. Other non-glomerular kidney diseases.
• • 3. Heart failure.
• • 4. Breast feeding or pregnancy.
• • 5. Patients who received medications to treat hyperkalemia 4 weeks before study.
• • 6. Uncontrolled hypertension (BP \> 160/100).